Trial Profile
A phase I/II study of Erbitux in patients with EGFR-expressing metastatic colorectal cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Jan 2016
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Merck KGaA
- 18 Jan 2016 New trial record
- 06 Jun 2004 Interim results published at the American Society of Clinical Oncology (ASCO) 40th Annual Meeting, as per ImClone media release.